甲基酸的抗癌保护潜力:叙述性审查
Jorge Cadena-Iñiguez1, Edelmiro Santiago-Osorio2, Nancy Sánchez-Flores2
1Postgraduate College, Campus San Luis Potosí, Salinas de Hidalgo, San Luis Potosí 78622, Mexico.
Molecules (Basel, Switzerland)
|April 13, 2024
概括
青菜中发现的天然化合物原卡特丘酸 (PCA) 显示出显著的抗癌潜力. 研究强调了其多样化的生物活动,支持其作为有前途的癌症治疗替代方案的使用.
科学领域:
- 自然产品化学 自然产品化学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 癌症仍然是全球主要的死亡原因,需要新的治疗策略.
- 自然产品,特别是蔬菜中的化合物,由于它们的有益作用,为癌症控制提供了有前途的途径.
- 原酸 (PCA) 是一种具有广泛记录的生物活性的化合物.
研究的目的:
- 审查Protocatechuic acid (PCA) 的多样化的生物活动.
- 专注于PCA的抗癌潜力.
- 探索PCA在调节瘤发育至关重要的分子通路中的作用.
主要方法:
- 文献综述关于原卡特丘酸的现有研究.
- 对详细说明PCA生物效应的研究进行分析.
- 检查PCA对癌症相关分子通路的影响的研究.
主要成果:
- 甲基甲酸 (PCA) 具有众多有益的特性,包括抗炎,抗氧化,抗变异和抗癌活性.
- 已证明PCA有效保护各种健康问题,如代谢综合征和器官损伤.
- 有证据表明,PCA影响了参与癌症进展的多个分子途径.
结论:
- 原酸 (PCA) 具有显著的抗癌潜力.
- 由于PCA的多方面的生物活动,使其成为癌症治疗的有希望的候选者.
- 对PCA作用机制的进一步研究可能会导致新的癌症治疗策略.
更多相关视频
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
351
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
12.3K
相关概念视频
Cancer Prevention
6.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.2K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Vaccines
360
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
360
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
